Conversion to resectability using hepatic artery infusion plus systemic chemotherapy for the treatment of unresectable liver metastases from colorectal carcinoma

Journal of Clinical Oncology

Volumn 27, Issue 21, 2009, Pages 3465-3471

  Kemeny, Nancy E ^a   Huitzil Melendez, Fidel D ^a   Capanu, Marinela ^a   Paty, Philip B ^a   Fong, Yuman ^a   Schwartz, Lawrence H ^a   Jarnagin, William R ^a   Patel, Dina ^a   D'Angelica, Michael ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DEXAMETHASONE; FLOXURIDINE; HEPARIN; IRINOTECAN; OXALIPLATIN; ANTINEOPLASTIC AGENT; CAMPTOTHECIN; DRUG DERIVATIVE; PLATINUM COMPLEX;

ADULT; AGED; ALKALINE PHOSPHATASE BLOOD LEVEL; ANATOMY; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BILIRUBIN BLOOD LEVEL; CANCER CHEMOTHERAPY; CANCER SURGERY; CANCER SURVIVAL; CLINICAL TRIAL; COLORECTAL CARCINOMA; DIARRHEA; DISEASE ASSOCIATION; DRUG DOSE ESCALATION; FEMALE; HEMATOMA; HEPATIC ARTERY; HUMAN; LIVER INJURY; LIVER METASTASIS; MAJOR CLINICAL STUDY; MALE; NEUROTOXICITY; NEUTROPENIA; OVERALL SURVIVAL; POSTOPERATIVE COMPLICATION; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; SEX DIFFERENCE; SIDE EFFECT; TREATMENT RESPONSE; COLORECTAL TUMOR; INTRAARTERIAL DRUG ADMINISTRATION; LIVER TUMOR; METASTASIS; MULTIMODALITY CANCER THERAPY; PATHOLOGY; SEGMENTAL MASTECTOMY; TREATMENT OUTCOME;

ANTINEOPLASTIC AGENTS; CAMPTOTHECIN; COLORECTAL NEOPLASMS; COMBINED MODALITY THERAPY; DEXAMETHASONE; FEMALE; FLOXURIDINE; HUMANS; INFUSIONS, INTRA-ARTERIAL; LIVER NEOPLASMS; MASTECTOMY, SEGMENTAL; ORGANOPLATINUM COMPOUNDS; TREATMENT OUTCOME;

EID: 70249149719     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2008.20.1301     Document Type: Article

References (21)

1. Tomlinson JS, Jarnagin WR, DeMatteo RP, et al: Actual 10-year survival after resection of colorectal liver metastases defines cure. J Clin Oncol 25:4575-4580, 2007
2. Fong Y, Fortner J, Sun RL, et al: Clinical score for predicting recurrence after hepatic resection for metastatic colorectal cancer: Analysis of 1001 consecutive cases. Ann Surg 230:309-318, 1999; discussion 318-321
3. Benoist S, Brouquet A, Penna C, et al: Complete response of colorectal liver metastases after chemotherapy: Does it mean cure? J Clin Oncol 24:3939-3945, 2006
4. Adam R, et al: Complete pathologic response after preoperative chemotherapy for colorectal liver metastases: Myth or reality? J Clin Oncol 26:1635-1641, 2008
5. Scheele J: Hepatectomy for liver metastases. Br J Surg 80:274-276, 1993
6. Jarnagin WR, Conlon K, Bodniewicz J, et al: A clinical scoring system predicts the yield of diagnostic laparoscopy in patients with potentially resectable hepatic colorectal metastases. Cancer 91:1121-1128, 2001
7. Bismuth H, Adam R, Levi F: Resection of nonresectable liver metastases from colorectal cancer after neoadjuvant chemotherapy. Ann Surg 224:509-520, 1996
8. Adam RA, Ariche E, Giachetti A, et al: Five-year survival following hepatic resection after neo-adjuvant therapy for nonresectable colorectal. Ann Surg Oncol 8:347-353, 2001
9. Adam R, Laurent A, Azoulay D, et al: Two-stage hepatectomy: A planned strategy to treat irresectable liver tumors. Ann Surg 232:777-785, 2000
10. Folprecht G, Grothey A, Alberts S, et al: Neoadjuvant treatment of unresectable colorectal liver metastases: Correlation between tumour response and resection rates. Ann Oncol 16:1311-1319, 2005
11. Ensminger WD, Rosowsky A, Raso V: A clinical pharmacological evaluation of hepatic arterial infusions of 5-fluoro-2-deoxyuridine and 5-fluorouracil. Cancer Res 38:3784-3792, 1978
12. Collins JM: Pharmacologic rationale for regional drug delivery. J Clin Oncol 2:498-504, 1984
13. Kemeny N, Jarnaqin W, Paty P, et al: Phase I trial of systemic oxaliplatin combination chemotherapy with hepatic arterial infusion in patients with unresectable liver metastases from colorectal cancer. J Clin Oncol 23:4888-4896, 2005
14. Kemeny N, Daly J, Reichman B, et al: Intrahepatic or systemic infusion of fluorodeoxyuridine in patients with liver metastases from colorectal carcinoma: A randomized trial. Ann Intern Med 107:459-465, 1987
15. Miller AB, Hoogstraten B, Staquet M, Winkler A: Reporting results of cancer treatment. Cancer 47:207-214, 1981
16. Kemeny NE, Niedzwiecki D, Hollis DR, et al: Hepatic arterial infusion versus systemic therapy for hepatic metastases from colorectal cancer: A randomized trial of efficacy, quality of life, and molecular markers (CALGB 9481). J Clin Oncol 24:1395-1403, 2006
17. Alberts SR, Horvath WL, Sternfeld WC, et al: Oxaliplatin, fluorouracil, and leucovorin for patients with unresectable liver-only metastases from colorectal cancer: A North Central Cancer Treatment Group phase II study. J Clin Oncol 23:9243-9249, 2005
18. Pozzo CB, Cassano M, Quirino A, et al: Neoadjuvant treatment of unresectable liver disease with irinotecan and 5-fluorouracil plus folinic acid in colorectal cancer patients. Ann Oncol 15:933-939, 2004
19. Ho WM, Ma B, Mok T, et al: Liver resection after irinotecan, 5-fluorouracil, and folinic acid for patients with unresectable colorectal liver metastases: A multicenter phase II study by the Cancer Therapeutic Research Group. Med Oncol 22:303-312, 2005
20. Clavien PAS, Morse N, Selzner M, et al: Down-staging of hepatocellular carcinoma and liver metastases from colorectal cancer by selective intra-arterial chemotherapy. Surgery 131:433-442, 2002
21. Falcone A, Ricci S, Brunetti I, et al: Phase III trial of infusional fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) compared with infusional fluorouracil, leucovorin, and irinotecan (FOLFIRI) as first-line treatment for metastatic colorectal cancer: The Gruppo Oncologico Nord Ovest. J Clin Oncol 25:1670-1676, 2007